Re: Transition and Release Agreement Dear Rob:Consulting Agreement • February 7th, 2023 • Fresh Tracks Therapeutics, Inc. • Biological products, (no disgnostic substances)
This letter sets forth the substance of the Transition and Release Agreement (the “Agreement”) that Fresh Tracks Therapeutics, Inc., f/k/a Brickell Biotech, Inc., the parent of Brickell Sub (“Brickell Parent”) and Brickell Subsidiary, Inc., d/b/a Brickell Biotech, Inc. (“Brickell Sub” and, together with Brickell Parent, collectively the “Company”) and you have agreed to as you voluntarily transition from your employment as Chief Executive Officer of the Company. Except as expressly referenced herein, this Agreement supersedes and replaces all prior understandings and agreements, whether oral or written, regarding the terms and conditions of your employment with the Company, including but not limited to that certain Employment Agreement between you and the Company dated November 16, 2018 (“Employment Agreement”). Together, you and the Company may be referred to collectively as the “Parties” and the term “Party” may refer to either you or Company as the circumstances dictate.
